Aslung

Aslung is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for lung diseases. The company's research and development efforts are primarily focused on oncology and respiratory conditions, with a particular emphasis on non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis (IPF). Aslung utilizes a proprietary drug discovery platform to engineer molecules with enhanced lung tissue distribution and selectivity. Its lead candidate, AL-101, is a fourth-generation EGFR tyrosine kinase inhibitor designed to target the C797S resistance mutation. Founded by experienced pharmaceutical industry leaders, the company aims to provide transformative treatment options for patients with high unmet medical needs in pulmonary medicine.